Clinical Trials on Heart Failure;Ensayos clínicos en insuficiencia cardíaca

Revista Espanola de Cardiologia

Volumn 54, Issue SUPPL. 1, 2001, Pages 22-31

  Aguilar, Juan Cosín ^a   Martínez, Amparo Hernándiz ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Heart failure; Multicenter trials

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARDIOTONIC AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; PROPANOLAMINE DERIVATIVE; VASODILATOR AGENT;

CLINICAL TRIAL; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; HUMAN; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; SUDDEN DEATH; TIME;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AMIODARONE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARBAZOLES; CARDIOTONIC AGENTS; CLINICAL TRIALS; DEATH, SUDDEN, CARDIAC; DIURETICS; ENALAPRIL; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; MULTICENTER STUDIES; PROGNOSIS; PROPANOLAMINES; QUALITY OF LIFE; RISK FACTORS; TIME FACTORS; VASODILATOR AGENTS;

EID: 18044385427     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-1435.
2. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314: 1547-1552.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
4. Pfeffer MA, Braunwald E, Morje LA, Basta L, Brown EJ Jr, Cuddy TE et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-677.
5. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. The effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1994; 342: 821-828.
6. Ambrosioni E, Borghi C, Magnani B and the SMILE investigators. The effect of the angiotensin converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1993; 332: 80-85.
7. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K et al. The Trandolapril Cardiac Evaluation (TRACE) Study group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infaction. N Engl J Med 1995; 333: 1670-1676.
8. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systemic overview of individual data from 100.000 patients randomised trials. Circulation 1998; 93: 2202-2212.
9. Yusuf S, Sleight P, Poque J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
10. Swerdberg K, Kjekshus J, Snappm S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS 1. Eur Heart J 1999; 20: 136-139.
11. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril of life expectancy of patients with reduced left anterior function after acute myocardial infarction. TRACE Study Group Trandolapril Cardiac Evolution. Lancet 1999; 354: 9-12.
12. Swedberg K, Held P, Kjekhus J, Rasmussen K, Rydén L, Wedel H et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678-684.
13. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58.050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-685.
14. Guppo Italiano per lo Studio della Sopravivenza nell'infarcto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
15. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13.634 patients with suspected acute myocardial infarction: intensive report from The Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686-687.
16. Waagstein F, Hjalmarson A. Wasir HS. Apex cardiogram and systolic time intervals in acute myocardial infarction and effect of practolol. Br Heart J 1974; 36: 1109-1113.
17. Waagstein F, Hjalmarson A, Varnanskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-1026.
18. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979; I: 1374-1379.
19. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA et al. Beneficial effect of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
20. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
21. CIBIS-II Investigators and Committees. The Cardiac Insuficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.
22. Hjalmarson A, Goldstein S, Fagenberg B, Wedel H, Waagstein F, Kjekshus J et al. Effects of controlled-release metoprolol on total mortality, hospitalisations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HP). MERIT-HF Study Group. JAMA 2000; 283: 1295-1302.
23. Richardson A, Bayliss J, Scriven AJ, Parameshwan J, Poole Wilson PA, Sutton GC et al. Double bind comparison of captorpil alone against furosemide plus amiloride in mild heart failure. Lancet 1987; 2: 709-711.
24. The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting-enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]) Am J Cardiol 1996; 78: 902-907.
25. Cosín J, Díaz J. Effects of type of diuretic on mortality in patients with chronic congestive heart failure. Eur Heart J 2000; 21 (Supl): 296.
26. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK et al, on behalf of the PROVED Investigators Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955-962.
27. Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ et al, for the Radiance Study. Withdraval of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329: 1-7.
28. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
29. Lewis BS, Rabinowitz B, Schelesinger Z, Caspi A, Markiewicz W, Rosenfeld T et al. Effect of isosorbide-5-mononitrate on exercise performance and clinical status in patients with congestive heart failure. Results of the Nitratos in Congestive Heart Failure (NICF) Study. Cardiology 1999; 91: 1-7.
30. Califf RM, Adams KF, McKenna WJ, Gheorghiade M, Uretsky BF, McNulty SE et al. A randomized controlled trial of epoprosterol therapy for severe congestive heart failure: The Flolan Interventional Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54.
31. Packer M, Ronleau JL, Swedberg KB, Cohn J, Zische SM, Young JB et al, and the PROFILE Investigators. Effect of Florequinan on survival in chronic heart failure: preliminary results of the PROFILE Study. Circulation 1988; 4: 1610.
32. Anderson JC. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 1991; 121: 1956-1964.
33. Girbes AR, Zijlstra JG. Ibopamine and survival in severe congestive Heart failure: PRIME II. Lancet 1997; 349: 971-977.
34. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990; 336: 1-6.
35. The Multicenter Diltiazem Postinfarction Trial Research Group. The Effect of Diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-392.
36. The Danish Study Group on Verapamil in Myocardial Infarction. Secondary presentation with verapamil after myocardial infarction. Am J Cardiol 1990; 66: 331-401.
37. The Israeli Sprint Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomised intervention trial of Nifedipine in patients with acute myocardial infarction. Eur Heart J 1988; 9: 354-364.
38. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN et al. Effect of amlodipine on mortality and morbidity in severe chronic heart failure. N Engl J Med 1996; 335: 1107-1114.
39. Cohn J, Zische SM, Smith R, Anand I, Dunkman WB, Loeb H et al. Effect of calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril V-HEFT III. Circulation 1997; 96: 856-863.
40. Levine TB, Bernink PJ, Caspi A, Elkayam U, Geltman EM, Greenberg B et al. Effect of mibefradil a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure. The MACH-I study. Mortality Assessment in Congestive Heart Failure Trial. Circulation 2000; 101: 758-764.
41. Pratt CM, Moye LA. The cardiac arrhythmia suppression trial: background, interin results and implications. Am J Cardiol 1990; 65: 20B-29B.
42. The Cardiac Arrhythmias Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327: 227-233.
43. Julian DG, Camm AJ, Fangin G, Janse M, Muñoz A, Schwartz PJ et al. Randomized trial on effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. Lancet 1997; 349: 667-674.
44. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC et al. Amiodarone in patients with congestive heart failure and symptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.
45. Waldo AL, Camm AJ, de Ruyter H, Friedman PL, MacNeil DJ, Pauls JF et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet 1996; 348: 7-12.
46. Torp-Pedersen C, Moller M, Bloch-Thomsen L, Kober L, Sandoe E, Egstrup K et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857-865.
47. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The department of veterans affairs CHF-STAT investigators. Circulation 1998; 98: 2574-2579.
48. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
49. CIBIS Investigators and Committees. A randomised trial of fablockade in heart failure, the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.
50. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I et al. Randomized trial of losartan vs captopril in patients over 65 with heart failure. Lancet 1997; 349; 747-752.
51. Pitt B, Poole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
52. The BEST steering committee. Design of the b-blocker Evaluation Survival Trial (BEST). Am J Cardiol 1995; 75: 1220-1223.
53. Packer M, Poole-Wilson PA, Amstrong PW, Cleland JG, Horowitz JD, Massie BM et al. Comparative effects of low and high doses of the angiotensin-converting-enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318.
54. Farnsworth A. Angiotensin-converting enzyme inhibitors in heart failure: target dose prescription in elderly patients. Letters to the editor. Age Ageing 1998; 27: 653-659.
55. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 1993; 88: 107-115.
56. The Study Group on Diagnosis of Working Group on Heart Failure of the European Society of Cardiology. Increasing awareness and improving the management of heart failure in Europe: the IMPROVEMENT of HF initiative. Eur J Heart Fail 1999; 1: 139-144.
57. Cosín J, Balle P, Barrios V en nombre de los Investigadores del capítulo español del Improvement of Heart Failure. Improvement of Heart Failure (Programa para mejorar la evaluación y el manejo de la Insuficiencia Cardíaca). Capítulo Español. Rev Esp Cardiol 2000; 53 (Supl 2): 61.